Skip to main content

Table 2 Patients’ characteristics by the presence of low estimated glomerular filtration and by age groups

From: Diabetic kidney disease in the elderly: prevalence and clinical correlates

 

< 65 years

65–75 years

> 75 years

eGFR-

eGFR+

 

eGFR-

eGFR+

 

eGFR-

eGFR+

 

n = 54,297

n = 3941

p

n = 44,378

n = 12,304

p

n = 23,754

n = 18,921

p

Male sex

33,640 (62.0%)

2301 (58.4%)

< 0.001

25,773 (58.1%)

6696 (54.4%)

< 0.001

12,262 (51.6%)

8618 (45.5%)

< 0.001

Age (years)

56 ± 7

60 ± 5

< 0.001

70 ± 3

71 ± 3

< 0.001

80 ± 4

81 ± 4

< 0.001

Duration of diabetes (years)

8 ± 7

11 ± 9

< 0.001

11 ± 9

14 ± 9

< 0.001

14 ± 10

16 ± 11

< 0.001

Albuminuria

13,031 (24.0%)

1855 (47.1%)

< 0.001

11,126 (25.1%)

5000 (40.6%)

< 0.001

6770 (28.5%)

7605 (40.2%)

< 0.001

Retinopathy

6073 (11.2%)

925 (23.5%)

< 0.001

6208 (14.0%)

2565 (20.8%)

< 0.001

3168 (13.3%)

3311 (17.5%)

< 0.001

BMI (Kg/m2)

30.3 ± 5.7

31.8 ± 6.2

< 0.001

29.3 ± 5.0

30.5 ± 5.3

< 0.001

28.0 ± 4.6

28.8 ± 4.8

< 0.001

HbA1c (%)

7.3 ± 1.4

7.4 ± 1.5

< 0.001

7.1 ± 1.2

7.3 ± 1.3

< 0.001

7.2 ± 1.2

7.3 ± 1.3

< 0.001

Triglycerides ≥150 mg/dl

17,380 (33.8%)

1916 (52.0%)

< 0.001

10,902 (26.1%)

4792 (42.0%)

< 0.001

4696 (21.4%)

5781 (33.8%)

< 0.001

HDL < 40/< 50 mg/dL (Male/Female)

19,366 (38.3%)

1837 (51.1%)

< 0.001

12,780 (31.1%)

4939 (44.2%)

< 0.001

6188 (28.6%)

6998 (41.7%)

< 0.001

LDL ≥100 mg/dL

26,449 (52.8%)

1593 (45.1%)

< 0.001

18,723 (45.6%)

4820 (43.4%)

< 0.001

10,034 (46.5%)

7676 (45.9%)

0.061

Blood Pressure ≥ 140/85 mmHg

22,307 (47.6%)

1795 (54.0%)

< 0.001

21,453 (56.1%)

5701 (56.0%)

0.130

11,688 (58.8%)

8518 (56.6%)

< 0.001

Smokers

8406 (25.5%)

459 (20.4%)

< 0.001

3612 (14.5%)

823 (12.2%)

< 0.001

923 (7.7%)

570 (6.0%)

< 0.001

Cardiovascular therapy

 Lipid-lowering treatment

28,831 (53.1%)

2571 (65.2%)

< 0.001

27,130 (61.1%)

8360 (67.9%)

< 0.001

12,802 (53.9%)

10,996 (58.1%)

< 0.001

 Treatment with statins

25,854 (47.6%)

2148 (54.5%)

< 0.001

25,456 (57.4%)

7472 (60.7%)

< 0.001

12,224 (51.5%)

10,188 (53.8%)

< 0.001

 Treatment with fibrates

1982 (3.7%)

303 (7.7%)

< 0.001

927 (2.1%)

576 (4.7%)

< 0.001

310 (1.3%)

490 (2.6%)

< 0.001

 Antihypertensive treatment

31,773 (58.5%)

3296 (83.6%)

< 0.001

32,412 (73.0%)

10,619 (86.3%)

< 0.001

18,098 (76.2%)

16,226 (85.8%)

< 0.001

 Treatment with ACE-Is/ARBs

27,592 (50.8%)

2868 (72.8%)

< 0.001

27,773 (62.6%)

9165 (74.5%)

< 0.001

14,992 (63.1%)

13,431 (71.0%)

< 0.001

 Aspirin

8470 (15.6%)

997 (25.3%)

< 0.001

10,745 (24.2%)

3533 (28.7%)

< 0.001

6079 (25.6%)

5460 (28.9%)

< 0.001

Antidiabetic therapy

 Diet

3010 (5.5%)

139 (3.5%)

< 0.001

2566 (5.8%)

520 (4.2%)

< 0.001

1262 (5.3%)

732 (3.9%)

< 0.001

 Oral antidiabetic drugs

37,223 (68.6%)

1927 (48.9%)

< 0.001

30,103 (67.8%)

6276 (51.0%)

< 0.001

15,565 (65.5%)

9441 (49.9%)

< 0.001

 Oral drugs and insulin

8685 (16.0%)

775 (19.7%)

< 0.001

7477 (16.8%)

2429 (19.7%)

< 0.001

3878 (16.3%)

3390 (17.9%)

0.001

 Insulin

5379 (9.9%)

1100 (27.9%)

< 0.001

4232 (9.5%)

3079 (25.0%)

< 0.001

3049 (12.8%)

5358 (28.3%)

< 0.001

Q Score

  < 15

2345 (4.3%)

189 (4.8%)

0.259

1353 (3.0%)

455 (3.7%)

0.002

858 (3.6%)

735 (3.9%)

0.262

 15–25

14,230 (26.2%)

1145 (29.1%)

0.002

10,953 (24.7%)

3494 (28.4%)

< 0.001

6555 (27.6%)

5788 (30.6%)

< 0.001

  > 25

37,722 (69.5%)

2607 (66.2%)

< 0.001

32,072 (72.3%)

8355 (67.9%)

< 0.001

16,341 (68.8%)

12,398 (65.5%)

< 0.001

  1. The bold values refers to significant (p < 0.001) comparisons between patients with eGFR< 60 mL/min/1.73m2 (eGFR+) and those with values ≥ 60 mL/min/1.73m2 (eGFR-)